Search

Displaying results 4031 - 4040 of 7452 in total
  1. Drug

    E-2012

    go.drugbank.com/drugs/DB05171
    Experimental

    E-2012 is a gamma secretase modulator that is being evaluated as a potential new treatment for Alzheimer's disease.

  2. Drug

    3,5-Diiodotyrosine

    go.drugbank.com/drugs/DB03374
    Experimental

    In the biosynthesis of thyroid hormones, diiodotyrosine residues are coupled with other monoiodotyrosine or diiodotyrosine residues to form T4 or T3 thyroid hormones (THYROXINE and TRIIODOTHYRONINE).

  3. Drug

    RGN6024

    go.drugbank.com/drugs/DB33059
    Experimental

    It is designed as an orally administered, blood-brain barrier penetrant therapy for brain cancers, especially glioblastoma. … Reglagene announced FDA orphan drug designation for glioblastoma in 2024. RGN6024 remains investigational and is not an approved drug.

  4. Indication

    Mucopolysaccharidosis Type IVA

    go.drugbank.com/conditions/DBCOND0060256
    Drugs: Elosulfase alfa
    Synonyms: Morquio's syndrome, classic form
  5. Drug

    Xylazine

    go.drugbank.com/drugs/DB11477
    InvestigationalVet approved

    [A32545] Xylazine is not approved for human use and requires a veterinary licence for its purchase and use. … [L42680] The intentional and unintentional use of xylazine is a cause for concern due to its side effects.

  6. Drug

    Acetylleucine

    go.drugbank.com/drugs/DB13226
    Investigational

    Used for treating vestibular-related imbalance and vertigo.

  7. Drug

    UCB-1184197

    go.drugbank.com/drugs/DB05092
    Investigational

    (now UCB S.A.) and is a putative new drug for oral treatment of multiple sclerosis.

  8. Drug

    AP1081

    go.drugbank.com/drugs/DB05233
    Experimental

    A transdermal gel containing ethinyl estradiol and norelgestromin being investigated by Antares Pharma for use as a female contraceptive.

  9. Drug

    Hydrotalcite

    go.drugbank.com/drugs/DB13322
    ApprovedInvestigationalWithdrawn

    Categories: Drugs for Acid Related Disorders
  10. Drug

    EPC2407

    go.drugbank.com/drugs/DB05189
    Investigational

    It is intended for the treatment of advanced cancer patients with solid tumors that are well vascularized. … EPC2407 is a novel small molecule vascular disruption agent and apoptosis inducer for the treatment of patients with advanced solid tumors and lymphomas.